Company |
Location | Date | Amount (M) | Investors/Business Focus |
Cerexus | London |
7/98 |
ND | Cerexus was spun off from Cerebrus Ltd. to explore the use of sodium channel blockers for the treatment of stroke and other neurological disorders. |
Enzacta |
Salisbury | 7/98 | £2 | Enzacta raised £2M from 3i plc to develop cancer chemotherapies using a toolkit approach of targeting agents, enzymes and clearance agents. |
Hoeft Rademacher Ltd. | London | 1/98 | £6 |
Apax Partners invested £4M and Advent International invested £2M to finance the company's research on phosphoglycokines, extra-cellular messengers with effects similar to a number of peptide hormones and growth factors. |
Microgenics Ltd. |
Oxford | 7/98 | £2.5 |
Oxford Molecular plc provided £2.5M to develop screening systems for novel antibiotics that interfere with bacterial cell division and spore formation. |
Neutec Pharma |
Manchester |
6/98 | £7.3 | Neutec raised £7.3M from 3i plc and ABN AMRO. The company was founded to exploit observations that patients who recover from hospital-acquired infections by "superbugs" produce neutralizing antibodies. |
OraTol Ltd. | London | 6/98 | £5 | OraTol was spun out of Cortecs plc; 3-year financing of £5M was provided by Atlas Venture, JAFCO, Kokusai Finance Co. Ltd., Saito, Ito & Partners Co. Ltd. and 1 other (unnamed) investment fund; Cortecs retains a 75% stake in OraTol. OraTol is developing treatments for allergies and autoimmune diseases based on tolerizing strategies to downregulate the immune system. |
Roslin Bio-med | Edinburgh | 4/98 | £6 | 3i plc invested £6M in Roslin, which will use the money to develop the nuclear transfer technology that led to the creation of Dolly the sheep for biomedical applications, particularly xenotrans-plantation. |
Synomics Ltd. |
London |
8/98 | £4 | JAFCO Co. Ltd., Biotechnology Investments Ltd., TVM Techno Venture Management and 3i plc each invested £1M in Synomics, which will develop and market bioinformatics software. |